Theresa Westphal,Simon Peter Gampenrieder,Gabriel Rinnerthaler et al.
Theresa Westphal et al.
Oligometastatic disease characterizes a distinct subgroup of metastatic breast cancer patients that might benefit from different treatment strategies to achieve long-lasting remission and potentially cure. Those long-lasting remissions are ...
APPLY: A prospective observational study of clinical practice patterns of darbepoetin alfa use in patients with chemotherapy-induced anemia in Romania [0.03%]
DAWERONEM：一项关于darbepoetin alfa治疗化疗引起的贫血患者的临床实践模式的前瞻性观察研究
Nicoleta Mariana Berbec,Dana Lucia Stanculeanu,Nicoleta Sorina Badelita et al.
Nicoleta Mariana Berbec et al.
Purpose: The primary objective of this study was to evaluate the compliance of Romanian physicians with the national therapeutic protocol and international guidelines on treatment with erythropoiesis-stimulating agents in...
Lucian Beer,Maximilian Hochmair,Helmut Prosch
Lucian Beer
Immunotherapies comprise of a class of cancer therapies that are increasingly used for treatment of several cancer entities. Active immunotherapies encompassing immune checkpoint inhibitors are the most widespread class of immunotherapies, ...
Jakob Daniel Rudzki
Jakob Daniel Rudzki
IO treatments (immuno-oncology treatments) have become reality and are now daily practice or, in some cases, a daily challenge. New recommendations are being made with the prime purpose of increasing alertness and awareness as well as empha...
Chimeric antigen receptor T‑cell therapy-a hematological success story [0.03%]
嵌合抗原受体T细胞疗法——一场血液学的成功实践故事
Philipp Wohlfarth,Nina Worel,Georg Hopfinger
Philipp Wohlfarth
Chimeric antigen receptor (CAR) T cells are genetically engineered autologous cells that express an activating receptor targeted towards one or more tumoral antigens. After ex vivo production and re-infusion, they are able to proliferate in...
Systemic treatment of advanced non-small cell lung cancer: controversies and perspectives [0.03%]
晚期非小细胞肺癌系统治疗的争议与展望
Andreas Tiefenbacher,Robert Pirker
Andreas Tiefenbacher
Patients with advanced non-small cell lung cancer receive first-line therapy with chemotherapy, targeted therapies in case of tumors with driver mutations, and more recently also immune checkpoint inhibitors. Important controversies include...
David Wanner,Michael Steurer
David Wanner
At ASH (American Society of Hematology) 2017 three out of a plethora of trials showed remarkable and promising results. The combinations of venetoclax with rituximab and ibrutinib with venetoclax convinced with striking efficacy together wi...
Barbara Kiesewetter,Mircea Dediu,Rupert Bartsch
Barbara Kiesewetter
This article is not intended to be a comprehensive review of all highlights presented at the recent ESMO Annual Meeting, but rather a summary from a personal point of view in three very different fields of oncology. Breast cancer and lung c...
Pleural effusion in 11:14 translocation q1 multiple myeloma in the setting of proteasome inhibitor presents therapeutic complexity [0.03%]
免疫蛋白酶体抑制剂诱导的浆细胞瘤并发胸腔积液一例
Malik Ghannam,Maria Bryan,Erik Kuross et al.
Malik Ghannam et al.
Background: Primary malignant pleural effusion has been reported in about 134 cases of multiple myeloma (MM). Associated pleural effusions in cases of MM portend a poor prognosis and identifying them is highly relevant. R...
Short overview on the current standard of treatment in newly diagnosed multiple myeloma [0.03%]
新诊断多发性骨髓瘤治疗现状的简要概述
Ella Willenbacher,Agnes Balog,Wolfgang Willenbacher
Ella Willenbacher
The treatment of newly diagnosed multiple myeloma has changed dramatically over the past 20 years, from near uniform application of chemotherapy to a patient performance status- and risk-based approach. Furthermore, initiation of treatment ...